[Asia Economy Reporter Minji Lee] ToolGen announced on the 16th that it has decided to construct the Osong R&D Center with a budget of 10 billion KRW. This corresponds to 10.12% of its equity capital.



The company stated, "This is to carry out the CRISPR gene-editing R&D project and to create network synergy among clusters within the Osong Advanced Medical Complex." The investment period is until December 16, 2023.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing